Stromal architecture and periductal decorin are potential prognostic markers for ipsilateral locoregional recurrence in ductal carcinoma in situ of the breast

Histopathology

Volumn 63, Issue 4, 2013, Pages 520-533

  Van Bockstal, Mieke ^a   Lambein, Kathleen ^a   Gevaert, Olivier ^b,c   De Wever, Olivier ^a   Praet, Marleen ^a   Cocquyt, Veronique ^a   Van den Broecke, Rudy ^a   Braems, Geert ^a   Denys, Hannelore ^a   Libbrecht, Louis ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c STANFORD UNIVERSITY   (United States)

Author keywords

Breast; DCIS; Decorin; Ductal carcinoma in situ; Invasive recurrence; Ipsilateral locoregional recurrence; Myxoid stroma; Prognostic biomarkers; Protein expression

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; AQUAPORIN 1; CAVEOLIN 1; CAVEOLIN 2; CD34 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; DECORIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; LAMININ BETA2; NECDIN; PROGESTERONE RECEPTOR; TAMOXIFEN; UNCLASSIFIED DRUG;

ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; MASTECTOMY; PARTIAL MASTECTOMY; PRIORITY JOURNAL; PROTEIN EXPRESSION; STROMA;

BREAST; DCIS; DECORIN; DUCTAL CARCINOMA IN SITU; INVASIVE RECURRENCE; IPSILATERAL LOCOREGIONAL RECURRENCE; MYXOID STROMA; PROGNOSTIC BIOMARKERS; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; DECORIN; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; TUMOR MARKERS, BIOLOGICAL; TUMOR MICROENVIRONMENT;

EID: 84884712573     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12188     Document Type: Article

References (44)

1. Pinder SE. Ductal carcinoma in situ (DCIS): pathological features, differential diagnosis, prognostic factors and specimen evaluation. Mod. Pathol. 2010; 23(Suppl. 2); S8-S13.
2. Rosner D, Bedwani RN, Vana J, Baker HW, Murphy GP. Non-invasive breast-carcinoma-results of a national survey by the American College of Surgeons. Ann. Surg. 1980; 192; 139-147.
3. Glover JA, Bannon FJ, Hughes CM et al. Increased diagnosis and detection rates of carcinoma in situ of the breast. Breast Cancer Res. Treat. 2012; 133; 779-784.
4. Wapnir IL, Dignam JJ, Fisher B et al. Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP b-17 and b-24 randomized clinical trials for DCIS. J. Natl Cancer Inst. 2011; 103; 478-488.
5. Silverstein MJ. The university of southern California/van Nuys prognostic index for ductal carcinoma in situ of the breast. Am. J. Surg. 2003; 186; 337-343.
6. Rudloff U, Jacks LM, Goldberg JI et al. Nomogram for predicting the risk of local recurrence after breast-conserving surgery for ductal carcinoma in situ. J. Clin. Oncol. 2010; 28; 3762-3769.
7. Han K, Nofech-Mozes S, Narod S et al. Expression of her2neu in ductal carcinoma in situ is associated with local recurrence. Clin. Oncol. 2012; 24; 183-189.
8. Altintas S, Lambein K, Huizing MT et al. Prognostic significance of oncogenic markers in ductal carcinoma in situ of the breast: a clinicopathologic study. Breast J. 2009; 15; 120-132.
9. Holmes P, Lloyd J, Chervoneva I et al. Prognostic markers and long-term outcomes in ductal carcinoma in situ of the breast treated with excision alone. Cancer 2011; 117; 3650-3657.
10. Kerlikowske K, Molinaro AM, Gauthier ML et al. Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis. J. Natl Cancer Inst. 2010; 102; 627-637.
11. Witkiewicz AK, Dasgupta A, Nguyen KH et al. Stromal caveolin-1 levels predict early DCIS progression to invasive breast cancer. Cancer Biol. Ther. 2009; 8; 1071-1079.
12. Yi M, Meric-Bernstam F, Kuerer HM et al. Evaluation of a breast cancer nomogram for predicting risk of ipsilateral breast tumor recurrences in patients with ductal carcinoma in situ after local excision. J. Clin. Oncol. 2012; 30; 600-607.
13. Provenzano E, Hopper JL, Giles GG, Marr G, Venter DJ, Armes JE. Biological markers that predict clinical recurrence in ductal carcinoma in situ of the breast. Eur. J. Cancer 2003; 39; 622-630.
14. Denys H, Braems G, Lambein K et al. The extracellular matrix regulates cancer progression and therapy response: implications for prognosis and treatment. Curr. Pharm. Des. 2009; 15; 1373-1384.
15. De Wever O, Demetter P, Mareel M, Bracke M. Stromal myofibroblasts are drivers of invasive cancer growth. Int. J. Cancer 2008; 123; 2229-2238.
16. Rudnick JA, Kuperwasser C. Stromal biomarkers in breast cancer development and progression. Clin. Exp. Metastasis 2012; 29; 663-672.
17. Yazhou C, Wenlv S, Weidong Z, Licun W. Clinicopathological significance of stromal myofibroblasts in invasive ductal carcinoma of the breast. Tumour Biol. 2004; 25; 290-295.
18. Pavlakis K, Messini I, Vrekoussis T et al. The assessment of angiogenesis and fibroblastic stromagenesis in hyperplastic and pre-invasive breast lesions. BMC Cancer 2008; 8; 88-95.
19. Barth PJ, Ebrahimsade S, Ramaswamy A, Moll R. Cd34 + fibrocytes in invasive ductal carcinoma, ductal carcinoma in situ, and benign breast lesions. Virchows Arch. 2002; 440; 298-303.
20. Witkiewicz AK, Freydin B, Chervoneva I et al. Stromal CD10 and SPARC expression in ductal carcinoma in situ (DCIS) patients predicts disease recurrence. Cancer Biol. Ther. 2010; 10; 391-396.
21. Fisher ER, Land SR, Saad RS et al. Pathologic variables predictive of breast events in patients with ductal carcinoma in situ. Am. J. Clin. Pathol. 2007; 128; 86-91.
22. Pinder SE, Duggan C, Ellis IO et al. A new pathological system for grading DCIS with improved prediction of local recurrence: results from the UKCCCR/ANZ DCIS trial. Br. J. Cancer 2010; 103; 94-100.
23. Cornfield DB, Palazzo JP, Schwartz GF et al. The prognostic significance of multiple morphologic features and biologic markers in ductal carcinoma in situ of the breast: a study of a large cohort of patients treated with surgery alone. Cancer 2004; 100; 2317-2327.
24. Gevaert O, Daemen A, De Moor B, Libbrecht L. A taxonomy of epithelial human cancer and their metastases. BMC Med. Genomics 2009; 2; 69-84.
25. Pinder SE, Ellis IO, Schnitt SJ, Tan PH, Rutgers E, Morrow M. Microinvasive carcinoma. In Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, van de Vijver MJ eds. World Health Organization classification of tumours. Geneva, Switzerland: WHO Press, 2012; 95-97.
26. Wernicke M, Pineiro LC, Caramutti D et al. Breast cancer stromal myxoid changes are associated with tumor invasion and metastasis: a central role for hyaluronan. Mod. Pathol. 2003; 16; 99-107.
27. Lambein K, Praet M, Forsyth R et al. Relationship between pathological features, HER2 protein expression and HER2 and CEP17 copy number in breast cancer: biological and methodological considerations. J. Clin. Pathol. 2011; 64; 200-207.
28. Wolff AC, Hammond ME, Schwartz JN et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch. Pathol. Lab. Med. 2007; 131; 18-43.
29. Allred DC, Clark GM, Elledge R et al. Association of p53 protein expression with tumor-cell proliferation rate and clinical outcome in node-negative breast-cancer. J. Natl Cancer Inst. 1993; 85; 200-206.
30. Hammond MEH, Hayes DF, Dowsett M et al. American society of clinical oncology/college of American pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch. Pathol. Lab. Med. 2010; 134; E48-E72.
31. Sloan EK, Ciocca DR, Pouliot N et al. Stromal cell expression of caveolin-1 predicts outcome in breast cancer. Am. J. Pathol. 2009; 174; 2035-2043.
32. Simpkins SA, Hanby AM, Holliday DL, Speirs V. Clinical and functional significance of loss of caveolin-1 expression in breast cancer-associated fibroblasts. J. Pathol. 2012; 227; 490-498.
33. Leygue E, Snell L, Dotzlaw H et al. Lumican and decorin are differentially expressed in human breast carcinoma. J. Pathol. 2000; 192; 313-320.
34. Allred DC, Anderson SJ, Paik S et al. Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol b-24. J. Clin. Oncol. 2012; 30; 1268-1273.
35. Millar EK, Tran K, Marr P, Graham PH. P27kip-1, cyclin A and cyclin D1 protein expression in ductal carcinoma in situ of the breast: P27kip-1 correlates with hormone receptor status but not with local recurrence. Pathol. Int. 2007; 57; 183-189.
36. Knudsen ES, Pajak TF, Qeenan M et al. Retinoblastoma and phosphate and tensin homolog tumor suppressors: impact on ductal carcinoma in situ progression. J. Natl Cancer Inst. 2012; 104; 1825-1836.
37. Wernicke M, Roitman P, Manfre D, Stern R. Breast cancer and the stromal factor. The 'prometastatic healing process' hypothesis. Medicina (Buenos Aires) 2011; 71; 15-21.
38. Savage K, Leung S, Todd SK et al. Distribution and significance of caveolin 2 expression in normal breast and invasive breast cancer: an immunofluorescence and immunohistochemical analysis. Breast Cancer Res. Treat. 2008; 110; 245-256.
39. Danielson KG, Baribault H, Holmes DF, Graham H, Kadler KE, Iozzo RV. Targeted disruption of decorin leads to abnormal collagen fibril morphology and skin fragility. J. Cell Biol. 1997; 136; 729-743.
40. Hallberg G, Andersson E, Naessen T, Ordeberg GE. The expression of syndecan-1, syndecan-4 and decorin in healthy human breast tissue during the menstrual cycle. Reprod. Biol. Endocrinol. 2010; 8; 35-41.
41. Bostrom P, Sainio A, Kakko T, Savontaus M, Soderstrom M, Jarvelainen H. Localization of decorin gene expression in normal human breast tissue and in benign and malignant tumors of the human breast. Histochem. Cell Biol. 2013; 139; 161-171.
42. Goldoni S, Seidler DG, Heath J et al. An antimetastatic role for decorin in breast cancer. Am. J. Pathol. 2008; 173; 844-855.
43. Santra M, Eichstetter I, Iozzo RV. An anti-oncogenic role for decorin. Down-regulation of ERBB2 leads to growth suppression and cytodifferentiation of mammary carcinoma cells. J. Biol. Chem. 2000; 275; 35153-35161.
44. Troup S, Njue C, Kliewer EV et al. Reduced expression of the small leucine-rich proteoglycans, lumican, and decorin is associated with poor outcome in node-negative invasive breast cancer. Clin. Cancer Res. 2003; 9; 207-214.